Dimethylarginine dimethylaminohydrolase 2 (DDAH2)

Dimethylarginine dimethylaminohydrolase 2 (DDAH2) is a protein encoded by the DDAH2 gene and classified as a putative hydrolase. While it shares sequence similarity with DDAH1, which hydrolyzes asymmetric dimethylarginine (ADMA), DDAH2 does not hydrolyze ADMA or participate directly in ADMA metabolism[1]. Instead, DDAH2 contributes to vascular and metabolic homeostasis by inducing the expression of vascular endothelial growth factor (VEGF) via phosphorylation of SP1, a process independent of nitric oxide and NO synthase activity[1][4]. DDAH2 expression is regulated by acetylation and transcription factors such as NF-κB, with relevance for renal nitric oxide signaling[2]. Genetic and transcriptional modulation of DDAH2 has been associated with conditions such as chronic kidney disease, cardiovascular dysfunction, sepsis, and pre-eclampsia[3][4]. It does not currently have direct interacting drugs or a defined mechanism of drug action, and its role as a biomarker is limited compared to DDAH1[3][4].

Other names

Putative hydrolase DDAH2DDAHG6ANG30DDAH-2Inactive dimethylarginine dimethylaminohydrolase 2DDAHIIInactive N(G),N(G)-dimethylarginine dimethylaminohydrolase 2Protein G6aS-phase proteindimethylargininase-2dimethylarginine dimethylaminohydrolase IIepididymis secretory protein Li 277testis tissue sperm-binding protein Li 54eHEL-S-277